Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDITION JUNIOR: Toujeo vs Lantus in Pediatric T1DM
NCT02735044Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2016
- Primary completion
- May 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of insulin glargine in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Sanofi. Primary endpoint: Change From Baseline in HbA1c at Month 6. Started Apr 2016; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02735044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02735044.